XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (492,024) $ (139,905)
Adjustments to reconcile net loss to net cash used in operating activities:    
Goodwill Impairment 357,585  
Depreciation and amortization expense 14,950 13,132
Provisions for credit losses (21) (308)
Amortization of deferred contract acquisition costs 1,093 847
Amortization of deferred contract fulfillment costs 215 288
Noncash compensation costs incurred by selling shareholders   3,993
Stock-based compensation expense 42,685 27,598
Loss on equity method investment 1,277 762
Deferred income taxes (23) (1,164)
Changes in operating assets and liabilities, net of acquisition:    
Accounts receivable 10,161 5,763
Inventories 205 (391)
Deferred contract acquisition costs (2,338) (1,135)
Prepaid expenses and other current assets 1,091 (1,714)
Other assets (212) 489
Accounts payable (2,753) (6,525)
Accrued expenses and other current liabilities (11,591) (490)
Other long-term liabilities   (15)
Deferred revenue 10,924 (6,624)
Net cash used in operating activities (68,776) (105,399)
Cash flows from investing activities:    
Purchases of property and equipment (36) (58)
Capitalized software development costs (13,836)  
Investment in less than majority owned joint venture (3,920) (1,960)
Purchases of investments (389,990) (499,223)
Proceeds from sales and maturities of investments 98,916 124,981
Net cash used in investing activities (308,866) (376,260)
Cash flows from financing activities:    
Proceeds from exercise of common stock options 569 4,465
Proceeds from employee stock purchase plan 1,268 1,501
Payments for the purchase of treasury stock (586)  
Proceeds from Section 16(b) disgorgement   295
Payment of contingent consideration   (11,790)
Net cash provided by (used in) financing activities 1,251 (5,529)
Effect of exchange rates changes on cash, cash equivalents, and restricted cash (799) (2,039)
Net decrease in cash, cash equivalents, and restricted cash (377,190) (489,227)
Cash, cash equivalents, and restricted cash at beginning of period 539,341 747,211
Cash, cash equivalents, and restricted cash at end of period 162,151 257,984
Cash, cash equivalents, and restricted cash at end of period:    
Cash and cash equivalents 161,356 257,189
Restricted cash 795 795
Total cash, cash equivalents, and restricted cash at end of period 162,151 257,984
Supplemental disclosure of cash flow information:    
Cash paid (refunded) for income taxes $ 1,018 13
Supplemental disclosure of non-cash investing and financing activities:    
Issuance of common stock in settlement of earnout   $ 17,243